Sugi Predict

Sugi Predict / Compounds / Pevonedistat

Pevonedistat

Pevonedistat

SCHEMBL936080

Cl.NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NAE1UBA3

The experimentally established mechanism targets of Pevonedistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ NAE1 known ✓ Q13564 18/20 0.98
▸ UBA3 known ✓ Q8TBC4 16/20 0.98
▸ UBA6 A0AVT1 3/20 0.98
▸ SAE1 Q9UBE0 3/20 0.98
▸ CA2 P00918 2/20 0.98
▸ GRK5 P34947 1/20 0.98
▸ CSNK1A1 P48729 1/20 0.98
▸ NEDD8 Q15843 1/20 0.98
▸ UBA2 Q9UBT2 1/20 0.98
▸ ATG7 O95352 1/20 0.57
▸ UBA7 P41226 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pevonedistat SCHEMBL30416991 1.00 NAE1 (0.98) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL31142629 1.00 NAE1 (0.98) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL10048256 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL14328898 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL10016613 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL23833815 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL1800436 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL20603286 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL22472958 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2
Pevonedistat SCHEMBL23924438 0.99 NAE1 (1.00) NAE1UBA3UBA6SAE1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368165-A1 SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-11-07 — — US claimed
US-20170000792-A9 HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-01-05 — — US claimed
US-20160030432-A1 HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-02-04 — — US claimed
US-9187482-B2 Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-11-17 — — US claimed
US-20240368165-A1 SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-11-07 — — US disclosed
US-20240368165-A1 SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-11-07 — — US disclosed
WO-2022112951-A1 SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-06-02 — — WO disclosed
EP-3091020-B1 HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE MILLENNIUM PHARM INC (US) 2020-12-30 — — EP disclosed
US-10786505-B2 Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents MILLENNIUM PHARMACEUTICALS, INC. (US) 2020-09-29 — — US disclosed
EP-2996773-B1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS MILLENNIUM PHARM INC (US) 2020-09-16 — — EP disclosed
US-20180325904-A1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-11-15 — — US disclosed
US-10016427-B2 Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate Millennium Pharmacetuicals, Inc. (US) 2018-07-10 — — US disclosed
US-20160030432-A1 HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-02-04 — — US disclosed
US-20150366886-A1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT MILLENNIUM PHARM INC (US) 2015-12-24 — — US disclosed
US-9187482-B2 Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-11-17 — — US disclosed
US-8980850-B2 Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-03-17 — — US disclosed
US-20140249167-A1 Administration of NEDD8-Activating Enzyme Inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-04 — — US disclosed
US-20130116208-A1 ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-05-09 — — US disclosed
US-20120115892-A1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-05-10 — — US disclosed
US-20110021544-A1 HYDROCHLORIDE SALT OF ((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116208-A1 ADMINISTRATION OF A NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT NEDD8, NAE1, UBE2M NAE1 2/4885UBA3 4/4885UBA6 174/4885
US-20120115892-A1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR NEDD8, NAE1, CAND1 NAE1 2/4885UBA3 4/4885UBA6 147/4885
US-20170000792-A9 HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE SULT1E1, SULT1A1, SULT2A1 NAE1 37/4885UBA3 296/4885UBA6 2934/4885
US-10016427-B2 Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate SULT1E1, SULT1A1, STS NAE1 39/4885UBA3 424/4885UBA6 3883/4885
US-20140249167-A1 Administration of NEDD8-Activating Enzyme Inhibitor NEDD8, NAE1, CAND1 NAE1 2/4885UBA3 4/4885UBA6 147/4885
US-10786505-B2 Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents NEDD8, NAE1, CAND1 NAE1 2/4885UBA3 4/4885UBA6 236/4885
US-20150366886-A1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND HYPOMETHYLATING AGENT NEDD8, NAE1, UBE2M NAE1 2/4885UBA3 4/4885UBA6 158/4885
US-20240368165-A1 SOLID STATE FORMS OF HYDROCHLORIDE SALT OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE SULT1E1, SRM, SULT1A1 NAE1 4365/4885UBA3 4209/4885UBA6 4743/4885
US-20160030432-A1 HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE SULT1E1, SULT1A1, SULT2A1 NAE1 37/4885UBA3 296/4885UBA6 2934/4885
US-20180325904-A1 ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS NEDD8, NAE1, CAND1 NAE1 2/4885UBA3 4/4885UBA6 236/4885
US-20110021544-A1 HYDROCHLORIDE SALT OF ((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE SULT1E1, SULT1A1, SULT2A1 NAE1 37/4885UBA3 296/4885UBA6 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.